drugset / Trial / NCT05898256
Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2024-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1 g | Intravenous |